APA (7th ed.) Citation

K, S., M, B., E, M., R, T., M, W., C, U., . . . U, P. (2012). Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): Results of the LENAMAINT trial. Haematologica, 97(9), e34. https://doi.org/10.3324/haematol.2012.067629

Chicago Style (17th ed.) Citation

K, Sockel, et al. "Lenalidomide Maintenance After Allogeneic HSCT Seems to Trigger Acute Graft-versus-host Disease in Patients with High-risk Myelodysplastic Syndromes or Acute Myeloid Leukemia and Del(5q): Results of the LENAMAINT Trial." Haematologica 97, no. 9 (2012): e34. https://doi.org/10.3324/haematol.2012.067629.

MLA (9th ed.) Citation

K, Sockel, et al. "Lenalidomide Maintenance After Allogeneic HSCT Seems to Trigger Acute Graft-versus-host Disease in Patients with High-risk Myelodysplastic Syndromes or Acute Myeloid Leukemia and Del(5q): Results of the LENAMAINT Trial." Haematologica, vol. 97, no. 9, 2012, p. e34, https://doi.org/10.3324/haematol.2012.067629.